GSK opens first high-potency facility in Singapore to produce drugs for cancer treatment


GSK invested S$44m t in the new high potency manufacturing facility and laboratory further strengthening Jurong site capabilities to launch new products more quickly. This facility will  manufacture a key ingredient for antibody drug conjugates (ADCs).

Article Summary

GSK officially opened its first high-potency manufacturing and test facility in Jurong, Singapore with the capability to manufacture highly potent components for cancer treatments. The opening of the facility was officiated by Guest-of-Honour, Singapore’s Minister for Health, Mr. Ong Ye Kung, and Mr. Regis Simard, GSK’s President, Global Supply Chain. The $44 million high-potency facility is also the first in Singapore, strengthening the site’s capabilities to meet increasing demand for oncology treatments around the world. 

This facility is the first in Singapore capable of producing a key ingredient – a cytotoxic agent in antibody drug conjugates (ADCs) – to treat cancer. It is equipped with advanced features such as specialized equipment, automated operations, exceptional containment capabilities and strict cross-contamination control.

“GSK’s new facility in Jurong is a positive step as we continue to spearhead innovation in our supply chain to impact health and lives in Singapore and worldwide,” added Mr. Regis Simard, President, Global Supply Chain. “With new capabilities to handle high-potency components effectively, we are in a good position to explore new frontiers in oncology and embark on a new era of manufacturing and delivering breakthrough cancer treatments.”

“The opening of GSK’s new facility demonstrates how global healthcare companies can tap on Singapore’s world-class infrastructure and talent to deliver innovative new products,” said Ms. Jacqueline Poh, Managing Director of the Singapore Economic Development Board. “We look forward to deepening our long-standing partnership with GSK, as we work together to transform the biopharmaceutical manufacturing sector and create good jobs for Singaporeans.”

With the addition of the new facility, GSK has further strengthened the Jurong site capabilities as a New Product Introduction (NPI) site to launch new products more quickly. The capability to produce high potency components at scale helps to meet the increasing demand for oncology treatments around the world.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.

Source: GSK, 17th November 2022









Leave A Comment

Leave a Reply

Your email address will not be published.